StockGuru Spotlights November 8, 2011: NVLT Up As Much As 75%; EMPM UP As Much As 69% with Market Cap of $72M

StockGuru Spotlights November 8,  2011:  NVLT Up As Much As 75%; EMPM UP As Much As 69% with Market Cap of $72M

StockGuru Spotlights for November 7,  2011

TRON, APNT, ECCE INTZ, NECA, XCLL, FORC

Dear Members:

These Spotlights have made tremendous moves. As you can see, StockGuru brings you the very stocks you want on your radar, in your portfolio and to trade.

StockGuru Spotlight Date Symbol Purchase Price High Up As Much As Market Cap
October 26, 2011 BIOR $0.30 $0.45 50% $13.91M
October 26, 2011 CTIX $0.34 $0.41 21% $35.91M
October 25, 2011 TUCN $0.02 $0.0295 48% $1.23M
October 24, 2011 EMPM $0.17 $0.29 69% $71.82M
October 21, 2011 NVLT $0.60 $1.05 75% $25.48M

Novelos Therapeutics, Inc. (OTCBB: NVLT) is a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. The Company has three cancer-targeted compounds, which are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells. Thus, the therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy — efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.

There are countless programs that make it easy to get RSS feeds on your wireless phone as well. This is foolproof BUT ONLY IF YOU CHECK YOUR RSS FEED REGULARLY! RSS link on the site. We do not yet send out Spotlight Alerts by email, in an attempt to give your email box a break. Spotlights occur several times weekly, and are released ONLY when we see a valid reason. Occasionally, our Spotlights are compensated picks, but an editorial decision is made as to whether the situation qualifies as a market sensitive pick and we ALWAYS include a disclosure prominently if we include a company for which we have been compensated in either cash or shares.

StockGuru is in its Ninth Year!